The Latest Cardiac and Vascular News
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective […]
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a […]
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct and clarify certain information contained in the quotation of the Chief Executive Officer. All other […]
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Completed enrollment in the HALO Phase 2 trial for baxdrostat in patients with uncontrolled hypertension with 249 patients randomized; topline data expected in the second half […]
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial evaluating baxdrostat’s (CIN-107) utility in ameliorating complications of chronic kidney […]
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer Conference call and live webcast today at 8:30 AM […]
BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry and has served in numerous executive and board […]
CINCINNATI, Oct. 28, 2021 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business Development Officer (EVP, CFO and CBDO). “Terry gained broad financial and operational leadership experience at several high-profile and start-up companies, including in […]
CINCINNATI, Oct. 19, 2021 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) today announced the appointment of Mason W. Freeman, M.D., as Executive Vice President, Clinical Development responsible for leading all clinical development at CinCor. “Mason will be guiding the clinical development programs for CIN-107 for multiple potential indications, including hypertension,” […]
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The brigHTN study is a Phase 2 clinical trial evaluating the blood pressure lowering effects of CIN-107, […]
